Add-on Intravenous Immunoglobulins in Early Myositis
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
In patients with myositis early immunomodulation by intensive treatment ("hit-early/hit-hard"
principle) may induce faster reduction of disease activity and prevent chronic disability.
Intravenous immunoglobulin (IVIg) in addition to standard treatment with glucocorticoids may
be beneficial for this purpose: add-on IVIg improved symptoms in steroid-resistant myositis,
and first-line monotherapy IVIg led to a fast and clinically relevant response in a pilot
study in nearly 50% of patients with myositis.
Phase:
Phase 2
Details
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)